Pancreatic cancer is the fourth leading cause of death from cancer in the United States. More than 37,000 people nationwide will die from pancreatic cancer this year. The overall five-year survival is less than 4%. This dismal picture of pancreatic cancer is mainly due to the lack of early diagnosis and effective treatment for patients with advanced disease. TGen investigators are partners in inter-institutional, cross-functional research efforts to: (1) identify and validate biomarkers of diagnostic value, as well as those that constitute new drug targets in pancreatic cancer; (2) identify and optimize new agents that affect the activity of the targets (3) perform in vitro and in vivo evaluation of the agents, and take the most promising ones to clinical trials in patients with advanced pancreatic cancer.

Research Laboratories
Cancer Therapy Development Lab
Pancreatic Cancer Research Lab
Systems Biology Lab

Contact(s)
Kati Koktavy
Project Manager II
Office of Project Management
Translational Genomics Research Institute
13208 E Shea Blvd
Scottsdale, AZ 85259
PH: 602-358-8372

Sandra Rosewell, MBA
Associate Director, Laboratory Research
445 North Fifth Street
Phoenix, Arizona 85004
PH: 602-343-8462
srosewell@tgen.org